Marshall & Sullivan Inc. WA Buys 343 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Jun 22nd, 2023

Marshall & Sullivan Inc. WA lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,883 shares of the company’s stock after purchasing an additional 343 shares during the quarter. Johnson & Johnson comprises approximately 2.8% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 18th largest position. Marshall & Sullivan Inc. WA’s holdings in Johnson & Johnson were worth $4,632,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Scotia Capital Inc. lifted its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock worth $195,247,000 after buying an additional 17,440 shares in the last quarter. Duality Advisers LP purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $4,342,000. Beacon Harbor Wealth Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $509,000. Modera Wealth Management LLC boosted its stake in Johnson & Johnson by 18.0% during the fourth quarter. Modera Wealth Management LLC now owns 44,189 shares of the company’s stock valued at $7,806,000 after buying an additional 6,738 shares during the last quarter. Finally, Willis Investment Counsel boosted its stake in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares during the last quarter. 67.57% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $163.87 on Thursday. The firm has a market capitalization of $425.85 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 2.80 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The company’s 50-day moving average is $160.72 and its two-hundred day moving average is $163.68.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.67 EPS. Analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. Johnson & Johnson’s dividend payout ratio is 99.58%.

Analyst Ratings Changes

A number of equities analysts have commented on JNJ shares. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $171.57.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.